A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms

J. Segalés; A. Urniza; A. Alegre; T. Bru; E. Crisci; M. Nofrarías; S. López-Soria; M. Balasch; M. Sibila; Z. Xu; H. J. Chu; L. Fraile; J. Plana-Duran

doi:10.1016/j.vaccine.2009.09.084

A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms

J. Segalés, A. Urniza, A. Alegre, T. Bru, E. Crisci, M. Nofrarías, S. López-Soria, M. Balasch, M. Sibila, Z. Xu, H. J. Chu, L. Fraile, J. Plana-Duran

Department of Animal Health and Anatomy

Research output: Contribution to journal › Article › Research › peer-review

62 Citations (Scopus)

Abstract

The present study describes the effects of a commercially available genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) on clinical, pathological and virological features in three multi-site farms suffering from postweaning multisystemic wasting syndrome (PMWS). The vaccine product was able to reduce clinical signs, PCV2 viral load in lymphoid organs and/or sera, and overall mortality in nurseries and fattening units. This is the first time in which is shown that a PCV2 vaccine is able to decrease specifically PMWS-associated mortality. Another novelty of this study is the assessment of PMWS-like histological lesions in a large number of vaccinated and non-vaccinated pigs under field conditions. © 2009 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	7313-7321
Journal	Vaccine
Volume	27
Issue number	52
DOIs	https://doi.org/10.1016/j.vaccine.2009.09.084
Publication status	Published - 9 Dec 2009

Keywords

Porcine circovirus type 2 (PCV2)
Postweaning multisystemic wasting syndrome (PMWS)
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2009.09.084

Cite this

Segalés, J., Urniza, A., Alegre, A., Bru, T., Crisci, E., Nofrarías, M., López-Soria, S., Balasch, M., Sibila, M., Xu, Z., Chu, H. J., Fraile, L., & Plana-Duran, J. (2009). A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms. Vaccine, 27(52), 7313-7321. https://doi.org/10.1016/j.vaccine.2009.09.084

Segalés, J. ; Urniza, A. ; Alegre, A. ; Bru, T. ; Crisci, E. ; Nofrarías, M. ; López-Soria, S. ; Balasch, M. ; Sibila, M. ; Xu, Z. ; Chu, H. J. ; Fraile, L. ; Plana-Duran, J. / A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms. In: Vaccine. 2009 ; Vol. 27, No. 52. pp. 7313-7321.

@article{cb94de24f5cd48879dd18b7055b44ea6,

title = "A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms",

abstract = "The present study describes the effects of a commercially available genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) on clinical, pathological and virological features in three multi-site farms suffering from postweaning multisystemic wasting syndrome (PMWS). The vaccine product was able to reduce clinical signs, PCV2 viral load in lymphoid organs and/or sera, and overall mortality in nurseries and fattening units. This is the first time in which is shown that a PCV2 vaccine is able to decrease specifically PMWS-associated mortality. Another novelty of this study is the assessment of PMWS-like histological lesions in a large number of vaccinated and non-vaccinated pigs under field conditions. {\textcopyright} 2009 Elsevier Ltd. All rights reserved.",

keywords = "Porcine circovirus type 2 (PCV2), Postweaning multisystemic wasting syndrome (PMWS), Vaccine",

author = "J. Segal{\'e}s and A. Urniza and A. Alegre and T. Bru and E. Crisci and M. Nofrar{\'i}as and S. L{\'o}pez-Soria and M. Balasch and M. Sibila and Z. Xu and Chu, {H. J.} and L. Fraile and J. Plana-Duran",

year = "2009",

month = dec,

day = "9",

doi = "10.1016/j.vaccine.2009.09.084",

language = "English",

volume = "27",

pages = "7313--7321",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "52",

}

Segalés, J, Urniza, A, Alegre, A, Bru, T, Crisci, E, Nofrarías, M, López-Soria, S, Balasch, M, Sibila, M, Xu, Z, Chu, HJ, Fraile, L & Plana-Duran, J 2009, 'A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms', Vaccine, vol. 27, no. 52, pp. 7313-7321. https://doi.org/10.1016/j.vaccine.2009.09.084

A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms. / Segalés, J.; Urniza, A.; Alegre, A.; Bru, T.; Crisci, E.; Nofrarías, M.; López-Soria, S.; Balasch, M.; Sibila, M.; Xu, Z.; Chu, H. J.; Fraile, L.; Plana-Duran, J.

In: Vaccine, Vol. 27, No. 52, 09.12.2009, p. 7313-7321.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms

AU - Segalés, J.

AU - Urniza, A.

AU - Alegre, A.

AU - Bru, T.

AU - Crisci, E.

AU - Nofrarías, M.

AU - López-Soria, S.

AU - Balasch, M.

AU - Sibila, M.

AU - Xu, Z.

AU - Chu, H. J.

AU - Fraile, L.

AU - Plana-Duran, J.

PY - 2009/12/9

Y1 - 2009/12/9

N2 - The present study describes the effects of a commercially available genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) on clinical, pathological and virological features in three multi-site farms suffering from postweaning multisystemic wasting syndrome (PMWS). The vaccine product was able to reduce clinical signs, PCV2 viral load in lymphoid organs and/or sera, and overall mortality in nurseries and fattening units. This is the first time in which is shown that a PCV2 vaccine is able to decrease specifically PMWS-associated mortality. Another novelty of this study is the assessment of PMWS-like histological lesions in a large number of vaccinated and non-vaccinated pigs under field conditions. © 2009 Elsevier Ltd. All rights reserved.

AB - The present study describes the effects of a commercially available genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) on clinical, pathological and virological features in three multi-site farms suffering from postweaning multisystemic wasting syndrome (PMWS). The vaccine product was able to reduce clinical signs, PCV2 viral load in lymphoid organs and/or sera, and overall mortality in nurseries and fattening units. This is the first time in which is shown that a PCV2 vaccine is able to decrease specifically PMWS-associated mortality. Another novelty of this study is the assessment of PMWS-like histological lesions in a large number of vaccinated and non-vaccinated pigs under field conditions. © 2009 Elsevier Ltd. All rights reserved.

KW - Porcine circovirus type 2 (PCV2)

KW - Postweaning multisystemic wasting syndrome (PMWS)

KW - Vaccine

U2 - 10.1016/j.vaccine.2009.09.084

DO - 10.1016/j.vaccine.2009.09.084

M3 - Article

VL - 27

SP - 7313

EP - 7321

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 52

ER -

A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this